• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Lipoprotein (a) measurement: potential for personalized cardiovascular disease management in a patient with acute myocardial infarction.

作者信息

Zimodro Jakub Michal, Gąsecka Aleksandra, Arski Piotr, Schwarz Jonas, Banach Maciej, Gouni-Berthold Ioanna

机构信息

1 Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.

Center for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Faculty of Medicine and University Hospital, Cologne, Germany.

出版信息

Arch Med Sci. 2024 May 3;20(3):1043-1047. doi: 10.5114/aoms/188252. eCollection 2024.

DOI:10.5114/aoms/188252
PMID:39050163
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11264059/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b44b/11264059/70b0f50f09ae/AMS-20-3-188252-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b44b/11264059/70b0f50f09ae/AMS-20-3-188252-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b44b/11264059/70b0f50f09ae/AMS-20-3-188252-g001.jpg

相似文献

1
Lipoprotein (a) measurement: potential for personalized cardiovascular disease management in a patient with acute myocardial infarction.脂蛋白（a）检测：急性心肌梗死患者个性化心血管疾病管理的潜力
Arch Med Sci. 2024 May 3;20(3):1043-1047. doi: 10.5114/aoms/188252. eCollection 2024.
2
Baseline Lipoprotein(a) Levels and Long-Term Cardiovascular Outcomes After Acute Myocardial Infarction.急性心肌梗死后脂蛋白(a)基线水平与长期心血管结局。
J Korean Med Sci. 2023 Apr 3;38(13):e102. doi: 10.3346/jkms.2023.38.e102.
3
Risk of primary and recurrent acute myocardial infarction from lipoprotein(a) in men and women.男性和女性中脂蛋白（a）导致原发性和复发性急性心肌梗死的风险。
J Am Coll Cardiol. 1996 Oct;28(4):870-5. doi: 10.1016/s0735-1097(96)00238-0.
4
Impact of Low Baseline Low-Density Lipoprotein Cholesterol on Long-Term Postdischarge Cardiovascular Outcomes in Patients With Acute Myocardial Infarction.急性心肌梗死患者低基线低密度脂蛋白胆固醇对出院后长期心血管结局的影响。
J Am Heart Assoc. 2022 Sep 6;11(17):e025958. doi: 10.1161/JAHA.122.025958. Epub 2022 Aug 24.
5
Effect of intraoperative personalized goal-directed hemodynamic management on acute myocardial injury in high-risk patients having major abdominal surgery: a post-hoc secondary analysis of a randomized clinical trial.术中个体化目标导向性血流动力学管理对高危患者行大腹部手术后急性心肌损伤的影响：一项随机临床试验的事后二次分析。
J Clin Monit Comput. 2022 Dec;36(6):1775-1783. doi: 10.1007/s10877-022-00826-0. Epub 2022 Feb 24.
6
Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease.脂蛋白(a)升高与家族性高胆固醇血症对动脉粥样硬化性心血管疾病患者的等效影响。
J Am Coll Cardiol. 2022 Nov 22;80(21):1998-2010. doi: 10.1016/j.jacc.2022.09.021.
7
A Systematic Review on the Risk Modulators of Myocardial Infarction in the "Young"-Implications of Lipoprotein (a).脂蛋白（a）与“年轻”人群心肌梗死风险因素的系统评价
Int J Mol Sci. 2023 Mar 21;24(6):5927. doi: 10.3390/ijms24065927.
8
Prognostic impact of lipoprotein(a) levels during lipid management with statins after ST-elevation acute myocardial infarction.ST段抬高型急性心肌梗死后使用他汀类药物进行血脂管理期间脂蛋白(a)水平的预后影响
Coron Artery Dis. 2019 Dec;30(8):600-607. doi: 10.1097/MCA.0000000000000798.
9
Serum lipoprotein(a) concentrations do not change significantly in the immediate seven-day period post myocardial infarction.心肌梗死后紧接着的七天内，血清脂蛋白(a)浓度无显著变化。
Ann Clin Biochem. 2015 Jul;52(Pt 4):502-5. doi: 10.1177/0004563214559221. Epub 2014 Oct 24.
10
Trends in clinical, demographic, and biochemical characteristics of patients with acute myocardial infarction from 2003 to 2008: a report from the american heart association get with the guidelines coronary artery disease program.2003 年至 2008 年急性心肌梗死患者的临床、人口统计学和生物化学特征趋势：美国心脏协会 get with the guidelines 冠状动脉疾病计划的报告。
J Am Heart Assoc. 2012 Aug;1(4):e001206. doi: 10.1161/JAHA.112.001206. Epub 2012 Aug 24.

引用本文的文献

1
2024: The year in cardiovascular disease - the year of lipoprotein(a). Research advances and new findings.2024年：心血管疾病之年——脂蛋白(a)之年。研究进展与新发现。
Arch Med Sci. 2025 Feb 22;21(2):355-373. doi: 10.5114/aoms/202213. eCollection 2025.
2
Lipoprotein(a) and thromboembolism: current state of knowledge and unsolved issues.脂蛋白(a)与血栓栓塞：当前的知识现状及未解决的问题。
Arch Med Sci. 2024 Dec 13;20(6):1770-1783. doi: 10.5114/aoms/197357. eCollection 2024.

本文引用的文献

1
Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels.波兰心脏病学会（PCS）和波兰脂质协会（PoLA）专家关于脂蛋白(a)水平升高的诊断和管理的建议。
Arch Med Sci. 2024 Jan 31;20(1):8-27. doi: 10.5114/aoms/183522. eCollection 2024.
2
Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease?靶向脂蛋白(a)：RNA疗法能否成为预防心血管疾病的下一步方案？
Cardiol Ther. 2024 Mar;13(1):39-67. doi: 10.1007/s40119-024-00353-w. Epub 2024 Feb 21.
3
Lipoprotein(a): from Causality to Treatment.
脂蛋白(a)：从因果关系到治疗。
Curr Atheroscler Rep. 2024 Mar;26(3):75-82. doi: 10.1007/s11883-024-01187-6. Epub 2024 Jan 22.
4
Lipoprotein(a) Is Markedly More Atherogenic Than LDL: An Apolipoprotein B-Based Genetic Analysis.脂蛋白(a)的致动脉粥样硬化作用明显强于 LDL：基于载脂蛋白 B 的遗传分析。
J Am Coll Cardiol. 2024 Jan 23;83(3):385-395. doi: 10.1016/j.jacc.2023.10.039.
5
Comparative effectiveness of moderate-intensity statin with ezetimibe therapy versus high-intensity statin monotherapy in patients with acute coronary syndrome: a nationwide cohort study.中等强度他汀类药物联合依折麦布治疗与高强度他汀类药物单药治疗急性冠脉综合征患者的疗效比较：一项全国性队列研究。
Sci Rep. 2024 Jan 8;14(1):838. doi: 10.1038/s41598-024-51310-5.
6
Inclisiran: a new generation of lipid-lowering siRNA therapeutic.英克西兰：新一代降脂小干扰RNA疗法。
Front Pharmacol. 2023 Oct 13;14:1260921. doi: 10.3389/fphar.2023.1260921. eCollection 2023.
7
Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society.2022 年欧洲动脉粥样硬化学会脂蛋白(a)共识声明的常见问题及解答。
Atherosclerosis. 2023 Jun;374:107-120. doi: 10.1016/j.atherosclerosis.2023.04.012. Epub 2023 Apr 28.
8
Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a).英克西兰、低密度脂蛋白胆固醇和脂蛋白(a)
Pharmaceuticals (Basel). 2023 Apr 12;16(4):577. doi: 10.3390/ph16040577.
9
2022: the year in cardiovascular disease - the year of upfront lipid lowering combination therapy.2022年：心血管疾病之年——起始联合降脂治疗之年
Arch Med Sci. 2022 Nov 7;18(6):1429-1434. doi: 10.5114/aoms/156147. eCollection 2022.
10
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.小干扰 RNA 降低心血管疾病中的脂蛋白(a)。
N Engl J Med. 2022 Nov 17;387(20):1855-1864. doi: 10.1056/NEJMoa2211023. Epub 2022 Nov 6.